Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOXIRI in locally advanced or metastatic pancreatic adenocarcinoma
ChiCTR-OIC-17012827Phase 2Recruiting
- Sponsor
- Huadong Hospital, Fudan University
- Start
- Oct 2017
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tegafur, irinotecan and oxaliplatin in pancreatic adenocarcinoma (PDAC), sponsored by Huadong Hospital, Fudan University. Primary endpoint: Objective response rate. Started Oct 2017; status: recruiting.
02
Drugs
tegafuririnotecanoxaliplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR-OIC-17012827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-17012827.